MKA
REGN icon

M. Kulyk & Associates’s Regeneron Pharmaceuticals REGN Stock Holding History

M. Kulyk & Associates’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.03M Sell
12,878
-2,017
-14% -$1.37M 1.31% 31
2026
Q1 		$11.5M Buy
14,895
+91
+0.6% +$69.7K 2.15% 13
2025
Q4 		$11.4M Buy
14,804
+431
+3% +$293K 2.18% 13
2025
Q3 		$8.08M Buy
14,373
+10,368
+259% +$5.86M 1.64% 19
2025
Q2 		$2.1M Buy
4,005
+1,318
+49% +$736K 0.46% 51
2025
Q1 		$1.7M Buy
2,687
+528
+24% +$363K 0.39% 53
2024
Q4 		$1.54M Buy
+2,159
New +$1.81M 0.33% 52

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

M. Kulyk & Associates's REGN Position: Q2 2026 in Review

M. Kulyk & Associates reduced its Regeneron Pharmaceuticals (REGN) stake by 14% in Q2 2026, selling an estimated $1.37M and leaving 12,878 shares worth $8.03M. The position accounts for 1.31% of the portfolio, ranked #31.

M. Kulyk & Associates first reported a position in REGN in Q4 2024 and has held it in 7 quarters since. The position peaked at $11.5M in Q1 2026. 1,335 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • M. Kulyk & Associates held 12,878 shares of Regeneron Pharmaceuticals worth $8.03M as of Q2 2026.
  • M. Kulyk & Associates sold 2,017 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $1.37M.
  • Regeneron Pharmaceuticals made up 1.31% of M. Kulyk & Associates's portfolio in Q2 2026, its #31 holding.
  • M. Kulyk & Associates first reported a position in Regeneron Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
  • M. Kulyk & Associates's Regeneron Pharmaceuticals position peaked at $11.5M in Q1 2026.
  • 1,335 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on M. Kulyk & Associates's 13F filing for Q2 2026, filed 7 Aug 2026.